Genomics

I. Introduction to The C-Value Paradox C-Value is defined as “the amount of DNA per haploid cell or the number of kilobases per haploid cell at any given time” (Swift 1950). The C-Value Paradox states that C-Value or genome size does not always equal the number of genes contained within the genome or complexity of the organism. Order of magnitude is when more DNA than what is necessary to encode for proteins. The prokaryotic genome is much simpler than the complex genome of the eukaryote yet…

breeding Javan Batang cow with a domestic cow, and a chimeric duck with a chicken and one day the concept of de-extinction will turn it into reality. This will obviously allure interests of the Shorthorn readers as well as inform them about progress in genomic technology. UTA students will enjoy reading this…

The nature versus nurture argument is, and has been, one of the most hotly debated topics in modern science for decades. The argument of whether humans start out as a “blank slate” or Tabula Rasa, as opposed to being predisposed with certain environmental effects out of their control transcends even natural science and enters into the realms of philosophy and psychology. It is nearly undeniable that the ideas of Mendelian inheritance are sound theories, yet the argument for…

State of the Problem In its variety of forms, cancer is estimated to affect more than 14 million people per year, and is the cause the death of more than 8 million (National Cancer Institute). Despite millions of dollars of research in the field, and a concentrated effort by researchers around the globe, a panacea for cancer doesn’t exist, although much headway has been made in earlier detection and better treatment methods. Much of the difficulty in treating the disease lies in its diversity;…

Introduction: Pharmacogenomics is the study of how genes affect an individual’s response to drugs. This is a new field that combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop fruitful, safe medicines and doses that will be customized to a human genetic makeup. Now drugs that are available are “one size fits all,” but they do not effective for every person. It is very tough to augur that a person get benefit from drug or not, and…

In the article "Schizophrenia begins in the womb, study suggests" by Honor Whiteman on the Medical News Today discusses the research devoted to Schizophrenia. The article talks about the abnormal gene labeled FGFR1 that can impair brain development early on. The scientists believe that this research could then find treatments and maybe prevent schizophrenia in the utero. Treatments such as giving pregnant women a drug that could prevent the process developing in the fetus. They discuss that…

According to the behavior of this cancer, and my genomic status, I will most likely be affected. However, if I begin to look for symptoms now; I can now prevent future detrimental consequences. Some of the symptoms of Osteosarcoma are an aching pain in the bones or an obvious tumor where the joints in your…

Sequencing the human genome and interpreting the biomarkers have tremendously increased the field of medicine. Personalized medicine merges a patient’s genotype, physiology, and their predicted outcome to create a plan specialized for their condition this can include pharmaceuticals that are specially made for a particular set of nucleotide bases in DNA (Patel et al., 2013). Patients have legal rights to decide whether or not their health information is kept private (Ghosh, 2012). The issue with…

Joseph Brillinger - 101012500 BIOL 1010 ‐ Biotechnology and Society Assignment #1 The Carleton Prize for Biotechnology Robert W. Holley, H. Gobind Khorana, Marshall W. Nirenberg for winning the Nobel Prize in physiology or Medicine in 1968. They received this award for their interpretation of the genetic code, and its function in protein synthesis. Joseph Brillinger – 101012500 Khorana, Nirenberg and Holley won the 1968 Nobel Prize in Physiology or…

This hospital-based case-control study was conducted on 110 consecutively newly diagnosed LP patients and 120 apparently healthy, age and sex-matched, control subjects. The control group consisted of participants referred for non-inflammatory dermatological conditions such as chronic hair loss or coming with their relatives. They had no oral mucosal, systemic or autoimmune diseases, and had no history of LP. All subjects were recruited from the outpatient clinic of the Department of Dermatology,…